Skip to main content
. 2014 Aug 1;24(6):325–335. doi: 10.1089/cap.2013.0105

Table 3.

Nonserious Treatment-Emergent Adverse Events (TEAEs) in ≥5% of Patients in Either Treatment Group (Safety Analysis Set)

TEAE Quetiapine XR (n=92) Placebo (n=100)
Headache 20 (21.7) 12 (12.0)
Sedation 7 (7.6) 6 (6.0)
Dizziness 6 (6.5) 2 (2.0)
Somnolence 6 (6.5) 4 (4.0)
Diarrhea 5 (5.4) 1 (1.0)
Fatigue 5 (5.4) 2 (2.0)
Nausea 5 (5.4) 1 (1.0)
Irritability 2 (2.2) 5 (5.0)

XR, extended release.